07 Oct 2026, 15:25 IST
Zydus Lifesciences Limited
HDFC Securities · ADD · target Rs 1,240
The report expects 27% YoY revenue growth but a sharp margin correction due to absence of gRevlimid and gMyrbetriq royalty fees, listing it as a muted performer.
From Pharma and Healthcare Q2FY27 Preview HSIE, written by HDFC Securities. Orivam summarised it; the view is HDFC Securities's, not Orivam's.
Open the original PDF →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.